Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Breast implant litigation

This article was originally published in The Gray Sheet

Executive Summary

Breast implant litigation: Wayne County (Michigan) Circuit Judge Robert Colombo issues summary judgment March 20 dismissing silicone breast implant suits filed in Michigan against Dow Chemical, the company says. Ruling in Dow Chemical's favor, Judge Colombo accepts the company's defense that silicone breast implants were products of Dow Corning Corp., in which Dow Chemical holds a 50% equity stake, and that Dow Chemical never tested silicone products for human implantation. The ruling could impact "approximately 800 cases" filed against Dow Chemical in Michigan, the firm states. Similar rulings in 1996 dismissed Dow Chemical from all suits in New York and California related to the implants. The company currently is seeking summary judgment on silicone implant cases pending in other states...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT007805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel